Co-administration of soy isoflavones and Vitamin D in management of irritable bowel disease

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Co-administration of soy isoflavones and Vitamin D in management of irritable bowel disease. / Jalili, Mahsa; Hekmatdoost, Azita; Vahedi, Homayoon; Poustchi, Hossein; Khademi, Behnam; Saadi, Mohsen; Zemestani, Maryam; Janani, Leila.

In: P L o S One, Vol. 11, No. 8, e0158545, 2016.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jalili, M, Hekmatdoost, A, Vahedi, H, Poustchi, H, Khademi, B, Saadi, M, Zemestani, M & Janani, L 2016, 'Co-administration of soy isoflavones and Vitamin D in management of irritable bowel disease', P L o S One, vol. 11, no. 8, e0158545. https://doi.org/10.1371/journal.pone.0158545

APA

Jalili, M., Hekmatdoost, A., Vahedi, H., Poustchi, H., Khademi, B., Saadi, M., Zemestani, M., & Janani, L. (2016). Co-administration of soy isoflavones and Vitamin D in management of irritable bowel disease. P L o S One, 11(8), [e0158545]. https://doi.org/10.1371/journal.pone.0158545

Vancouver

Jalili M, Hekmatdoost A, Vahedi H, Poustchi H, Khademi B, Saadi M et al. Co-administration of soy isoflavones and Vitamin D in management of irritable bowel disease. P L o S One. 2016;11(8). e0158545. https://doi.org/10.1371/journal.pone.0158545

Author

Jalili, Mahsa ; Hekmatdoost, Azita ; Vahedi, Homayoon ; Poustchi, Hossein ; Khademi, Behnam ; Saadi, Mohsen ; Zemestani, Maryam ; Janani, Leila. / Co-administration of soy isoflavones and Vitamin D in management of irritable bowel disease. In: P L o S One. 2016 ; Vol. 11, No. 8.

Bibtex

@article{b800fe0610fd48d19117da1b1e9fe2c7,
title = "Co-administration of soy isoflavones and Vitamin D in management of irritable bowel disease",
abstract = "Background and Aims: The substantial characteristics of Irritable Bowel Syndrome (IBS) are associated with estrogens in women. Both soy isoflavones and vitamin D can modulate estrogen receptors in the colonic smooth muscles. The aim of this study was to investigate the effects of soy isoflavones, vitamin D and their probable interactions in women with IBS. Methods: In a factorial blinded randomized clinical trial, 100 women with IBS (age:18-75yr, were randomly assigned in 4 arms to receive either placebo of vitamin D and placebo of soy isoflavones (P+P), or placebo of vitamin D and soy isoflavones (P+S), or vitamin D and placebo of soy isoflavones (D+P), or vitamin D and soy isoflavones (D+S) for 6 weeks. Dosage of soy isoflavone was 2 capsules of 20 mg soy isoflavones per day, and dosage of vitamin D was one pearl of 50'000 IU biweekly. The clinical outcomes were IBS symptoms severity scores (IBS-SSS), disease- specific quality of life (IBS-QOL) and total score (IBS-TS) that evaluated at weeks 0, 6, and 10, and compared to each other. Results: IBS-TS improved significantly in both S+P and D+P groups (p- value = 0.004, 0.015). The interaction effect of soy isoflavones and vitamin D on IBS-TS was significant (p<0.05). The interaction effect of soy isoflavones with vitamin D and the main effect of vitamin D on IBS-SSS were not statistically significant, whereas IBS-SSS decreased significantly in S+P and D+P groups (p-value = 0.001, 0.047 respectively). Conclusion: Our results indicate that co-administration of soy isoflavones with vitamin D did not improve the IBS- SSS and IBS- QOL; however, it improved the IBS-TS. Trial Registration Clinical Trials.gov NCT02026518.",
author = "Mahsa Jalili and Azita Hekmatdoost and Homayoon Vahedi and Hossein Poustchi and Behnam Khademi and Mohsen Saadi and Maryam Zemestani and Leila Janani",
note = "(Ekstern)",
year = "2016",
doi = "10.1371/journal.pone.0158545",
language = "English",
volume = "11",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

RIS

TY - JOUR

T1 - Co-administration of soy isoflavones and Vitamin D in management of irritable bowel disease

AU - Jalili, Mahsa

AU - Hekmatdoost, Azita

AU - Vahedi, Homayoon

AU - Poustchi, Hossein

AU - Khademi, Behnam

AU - Saadi, Mohsen

AU - Zemestani, Maryam

AU - Janani, Leila

N1 - (Ekstern)

PY - 2016

Y1 - 2016

N2 - Background and Aims: The substantial characteristics of Irritable Bowel Syndrome (IBS) are associated with estrogens in women. Both soy isoflavones and vitamin D can modulate estrogen receptors in the colonic smooth muscles. The aim of this study was to investigate the effects of soy isoflavones, vitamin D and their probable interactions in women with IBS. Methods: In a factorial blinded randomized clinical trial, 100 women with IBS (age:18-75yr, were randomly assigned in 4 arms to receive either placebo of vitamin D and placebo of soy isoflavones (P+P), or placebo of vitamin D and soy isoflavones (P+S), or vitamin D and placebo of soy isoflavones (D+P), or vitamin D and soy isoflavones (D+S) for 6 weeks. Dosage of soy isoflavone was 2 capsules of 20 mg soy isoflavones per day, and dosage of vitamin D was one pearl of 50'000 IU biweekly. The clinical outcomes were IBS symptoms severity scores (IBS-SSS), disease- specific quality of life (IBS-QOL) and total score (IBS-TS) that evaluated at weeks 0, 6, and 10, and compared to each other. Results: IBS-TS improved significantly in both S+P and D+P groups (p- value = 0.004, 0.015). The interaction effect of soy isoflavones and vitamin D on IBS-TS was significant (p<0.05). The interaction effect of soy isoflavones with vitamin D and the main effect of vitamin D on IBS-SSS were not statistically significant, whereas IBS-SSS decreased significantly in S+P and D+P groups (p-value = 0.001, 0.047 respectively). Conclusion: Our results indicate that co-administration of soy isoflavones with vitamin D did not improve the IBS- SSS and IBS- QOL; however, it improved the IBS-TS. Trial Registration Clinical Trials.gov NCT02026518.

AB - Background and Aims: The substantial characteristics of Irritable Bowel Syndrome (IBS) are associated with estrogens in women. Both soy isoflavones and vitamin D can modulate estrogen receptors in the colonic smooth muscles. The aim of this study was to investigate the effects of soy isoflavones, vitamin D and their probable interactions in women with IBS. Methods: In a factorial blinded randomized clinical trial, 100 women with IBS (age:18-75yr, were randomly assigned in 4 arms to receive either placebo of vitamin D and placebo of soy isoflavones (P+P), or placebo of vitamin D and soy isoflavones (P+S), or vitamin D and placebo of soy isoflavones (D+P), or vitamin D and soy isoflavones (D+S) for 6 weeks. Dosage of soy isoflavone was 2 capsules of 20 mg soy isoflavones per day, and dosage of vitamin D was one pearl of 50'000 IU biweekly. The clinical outcomes were IBS symptoms severity scores (IBS-SSS), disease- specific quality of life (IBS-QOL) and total score (IBS-TS) that evaluated at weeks 0, 6, and 10, and compared to each other. Results: IBS-TS improved significantly in both S+P and D+P groups (p- value = 0.004, 0.015). The interaction effect of soy isoflavones and vitamin D on IBS-TS was significant (p<0.05). The interaction effect of soy isoflavones with vitamin D and the main effect of vitamin D on IBS-SSS were not statistically significant, whereas IBS-SSS decreased significantly in S+P and D+P groups (p-value = 0.001, 0.047 respectively). Conclusion: Our results indicate that co-administration of soy isoflavones with vitamin D did not improve the IBS- SSS and IBS- QOL; however, it improved the IBS-TS. Trial Registration Clinical Trials.gov NCT02026518.

UR - http://www.scopus.com/inward/record.url?scp=84983340553&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0158545

DO - 10.1371/journal.pone.0158545

M3 - Journal article

C2 - 27490103

AN - SCOPUS:84983340553

VL - 11

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 8

M1 - e0158545

ER -

ID: 248338738